12/2/2011

Type 2 diabetes patients on stable-dose insulin glargine who used the glucokinase inhibitor MK-0941 had better A1C and two-hour post-meal glucose levels at week 14, compared with those who took a placebo, according to a study in Diabetes Care. However, researchers found that such improvements in glycemic control were not sustained by 30 weeks.

Related Summaries